Pα+ Psychedelic Bulletin #202 covers US access timelines, Washington policy signals, Lykos leadership changes, New Zealand psilocybin prescribing, and DEA scheduling

Pα+ Psychedelic Bulletin #202 compiles multiple late June 2025 developments across policy, industry, and regulation. US coverage centers on comments tying psychedelic-assisted therapy access to a possible 12 month timeline, discussed in the context of federal agencies, VA clinical trials, and FDA guidance. The bulletin also tracks Washington related signals from FDA and VA stakeholders. Industry updates include leadership changes at Lykos, with both a new CEO and new CMO joining the board. Internationally, the bulletin notes New Zealand approving its first psilocybin prescriber. Regulatory risk is highlighted by a report that a DEA judge recommends keeping DOI and DOC in Schedule I placement, adding urgency to the US legal and scheduling landscape alongside the approval and access discussions.